Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114932

Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution.

L M Wakefield, T S Winokur, R S Hollands, K Christopherson, A D Levinson, and M B Sporn

Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Wakefield, L. in: PubMed | Google Scholar

Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Winokur, T. in: PubMed | Google Scholar

Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Hollands, R. in: PubMed | Google Scholar

Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Christopherson, K. in: PubMed | Google Scholar

Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Levinson, A. in: PubMed | Google Scholar

Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892.

Find articles by Sporn, M. in: PubMed | Google Scholar

Published December 1, 1990 - More info

Published in Volume 86, Issue 6 on December 1, 1990
J Clin Invest. 1990;86(6):1976–1984. https://doi.org/10.1172/JCI114932.
© 1990 The American Society for Clinical Investigation
Published December 1, 1990 - Version history
View PDF
Abstract

Transforming growth factor beta 1 (TGF-beta 1) is a key regulator of cell growth and differentiation. Under normal physiological conditions, it is made as a biologically latent complex whose significance is unknown. Previous work has indicated that active TGF-beta 1 has a very short plasma half-life in rats (Coffey, R. J., L. J. Kost, R. M. Lyons, H. L. Moses, and N. F. La-Russo. 1987. J. Clin. Invest. 80:750-757). We have investigated the possibility that latent complex formation may extend the plasma half-life of TGF-beta 1 and alter its organ distribution. Radiolabeled latent TGF-beta 1 was formed by noncovalent association of 125I-TGF-beta 1 with the TGF-beta 1 precursor "pro" region from recombinant sources. TGF-beta 1 in this latent complex had a greatly extended plasma half-life (greater than 100 min) in rats compared with active TGF-beta 1 (2-3 min). Whereas active TGF-beta 1 was rapidly taken up by the liver, kidneys, lungs, and spleen and degraded, TGF-beta 1 in the latent complex was largely confined to the circulation, and was less than 5% degraded after 90 min. The pharmacokinetics of TGF-beta 1 in the latent complex were shown to be critically dependent on the degree of sialylation of the complex. The results suggest that formation of latent complexes may switch endogenous TGF-beta 1 from an autocrine/paracrine mode of action to a more endocrine mode involving target organs distant from the site of synthesis.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1976
page 1976
icon of scanned page 1977
page 1977
icon of scanned page 1978
page 1978
icon of scanned page 1979
page 1979
icon of scanned page 1980
page 1980
icon of scanned page 1981
page 1981
icon of scanned page 1982
page 1982
icon of scanned page 1983
page 1983
icon of scanned page 1984
page 1984
Version history
  • Version 1 (December 1, 1990): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts